These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 23621668)

  • 1. Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.
    Tanasescu R; Constantinescu CS
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1219-28. PubMed ID: 23621668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Bazinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
    Podda G; Constantinescu CS
    Expert Opin Biol Ther; 2012 Nov; 12(11):1517-31. PubMed ID: 22954177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Basinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
    Moreno Torres I; Sanchez AJ; Garcia-Merino A
    Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials.
    Prieto González JM; Vila Silván C
    Expert Rev Neurother; 2021 Jul; 21(7):755-778. PubMed ID: 34092180
    [No Abstract]   [Full Text] [Related]  

  • 7. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
    Prieto González JM; Vila Silván C
    Expert Rev Neurother; 2021 May; 21(5):547-558. PubMed ID: 33749480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis.
    Gajofatto A
    Mult Scler Relat Disord; 2016 Jul; 8():64-5. PubMed ID: 27456876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
    Barnes MP
    Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic use of cannabinoids: Forensic aspects.
    Indorato F; Liberto A; Ledda C; Romano G; Barbera N
    Forensic Sci Int; 2016 Aug; 265():200-3. PubMed ID: 27038587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
    Carod-Artal FJ; Adjamian P; Vila Silván C; Bagul M; Gasperini C
    Expert Rev Neurother; 2022 Jun; 22(6):499-511. PubMed ID: 35582858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
    Iskedjian M; Bereza B; Gordon A; Piwko C; Einarson TR
    Curr Med Res Opin; 2007 Jan; 23(1):17-24. PubMed ID: 17257464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
    D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
    BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.
    Serpell M; Ratcliffe S; Hovorka J; Schofield M; Taylor L; Lauder H; Ehler E
    Eur J Pain; 2014 Aug; 18(7):999-1012. PubMed ID: 24420962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabis and multiple sclerosis.
    Fragoso YD; Carra A; Macias MA
    Expert Rev Neurother; 2020 Aug; 20(8):849-854. PubMed ID: 32515670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
    Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
    PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.